Hints and tips:
...Investors will still have to wait until at least 2026 for an approved oncology product....
...Jacob Van Naarden, president of the company’s oncology division Loxo@Lilly, said the acquisition of Point would be the “beginning of our investment in developing multiple meaningful radioligand medicines...
...The closely followed SPDR S&P Biotech ETF tumbled almost two-thirds from its 2021 high, weighed down by rising interest rates and a backlash to pandemic-era over-optimism about new drugs....
...SRT transactions have picked up, more than doubling globally to €200bn in the two years to 2022, according to data from S&P Global....
...to c.$1.2bn....
...Some would probably argue that more information is not the same as better information . . . but c’mon....
...The Soviet cosmonauts initially used pencils — before purchasing Paul C Fisher’s pens themselves in 1969....
...In contrast, the multi-manager model relies on specialist traders, overseen by sophisticated risk management technology, and a ruthless approach to hiring and firing by their paymasters....
...Higher risks make this a market for specialists. The perimeter of the financial junkyard is defined by a rating of BB+ from Fitch and S&P, and Ba1 from Moody’s....
...After assembling a team of specialists for a complicated job, a contractor falls asleep on a plane....
...ETFs struggle, however, to compete with trusts in more specialist corners of the investment universe....
...Business coach Julie Stokes has just helped launch a new executive retreat at Goodwood with gut-health specialist and psychotherapist Stephanie Moore....
...It achieved records in four of its five business units last year, with its fixed income strategy making 32.6 per cent, ahead of many specialist macro funds....
...By June next year, S&P Global is predicting the US default rate will rise to 4.5 per cent, up from 1.7 per cent at the start of 2023....
...This time, that index, which now includes larger biotechs, has fallen 28 per cent from its peak in early September last year, and the S&P XBI, of smaller companies, has fallen 41 per cent since last November...
...A total of 51 large retailers filed for bankruptcy in the US in 2020 — a decade high, according to S&P Global Market Intelligence....
...While ETFs tracking the S&P Global Clean Energy Index received an A+ score from TrackInsight, others, such as those replicating the MSCI USA Extended ESG Focus index, were given a C+ (D is the lowest score...
...But it has fewer side effects than chemotherapy or radiation and this can reduce the overall costs of care....
...Varian is a world leader in the field of cancer care, in particular radiation oncology, and uses artificial intelligence, machine learning and data analysis to improve cancer treatment....
...Gilead Sciences has spent years and billions of dollars developing its oncology business....
...For Gilead this would be the third blockbuster oncology-focused deal in three years....
...Here’s Goldman: Varian is the market leader in the global radiation oncology market, with c.60% market share, with Elekta the other sizeable player, at c.40% market share....
...When women do reach the C-suite in Germany, it is sometimes to resolve problems left by male predecessors....
...If the bondholders call in their debt, M&B could sell some of its 1,356 securitised pubs (last valued at c£4bn) to pay off c£1.7bn of notes and c£0.3bn of MTM swaps....
...“This agreement builds on Gilead’s presence in immuno-oncology and adds significant potential to our clinical pipeline,” said Daniel O’Day, Gilead’s chief executive....
International Edition